Colesevelam hydrochloride: A specifically engineered bile acid sequestrant

Future Lipidology

Volumn 3, Issue 3, 2008, Pages 237-255

  Manghat, Padmini ^a   Wierzbicki, Anthony S ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Bile acid sequestrant; Cardiovascular; Cholesterol; Colesevelam HCl; Diabetes

Indexed keywords

ATORVASTATIN; BILE ACID SEQUESTRANT; CHOLESTEROL; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; DIGOXIN; ETHINYLESTRADIOL PLUS NORETHISTERONE; EZETIMIBE; FENOFIBRATE; GLIBENCLAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOTHYROXINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; METOPROLOL; MEVINOLIN; NICOTINIC ACID; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PLACEBO; PRAVASTATIN; PROPRANOLOL; QUINIDINE; SIMVASTATIN; SULFONYLUREA; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; WARFARIN;

ADD ON THERAPY; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG USE; DYSPEPSIA; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; INFECTION; ISCHEMIC HEART DISEASE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 47649113235     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460875.3.3.237     Document Type: Article

References (74)

1. Shepherd J, Cobbe SM, Ford I 1 et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333(20), 1301-1037 (1995).
2. Sacks FM, Pfeffer MA, Moye LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335(14), 1001-1009 (1996).
3. Baigent C, Keech A, Kearney PM et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267-1278 (2005).
4. Taylor AJ, Kent SM, Flaherty PJ et al.: ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 106(16), 2055-2060 (2002).
5. Nissen SE, Tuzcu EM, Schoenhagen P et al.: Effect of Intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291(9), 1071-1080 (2004).
6. Cannon CP, Braunwald E, McCabe CH et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350(15), 1495-1504 (2004).
7. Corti R, Fuster V, Fayad ZA et al.: Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J. Am. Coll. Cardiol. 46(1), 106-112 (2005).
8. Nissen SE, Nicholls SJ, Sipahl I et al.: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295(13), 1556-1565 (2006).
9. Brown BG, Taylor AJ: Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N. Engl. J. Med. 358(14), 1504-1507 (2008).
10. The Lipid Research Clinics Coronary Primary Prevention Trial results: I. Reduction in incidence of coronary heart disease. JAMA 251(3), 351-364 (1984).
11. Colesevelam: GT 31104, CholestaGel. Drugs R D 1(6), 479-480 (1999).
12. Insull W Jr: Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med. J. 99(3), 257-273 (2006).
13. Holmes-Farley SR, Mandeville HW, Miller KL et al.: Colesevelam hydrochloride:synthesis and testing of a novel polymer gel pharmaceutical. Polymer Prepr. 41(1), 735-736 (2000).
14. Bays H, Dujovne C: Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin. Pharmacother. 4(5), 779-790 (2003).
15. Braunlin W, Zhorov E, Smisek D et al.: In vitro comparison of bile acid binding to colesevelam HC1 and other bile acid sequestrants. Polymer Prepr. 41(1), 708-709 (2000).
16. Brown DD, Schmid J, Long RA et al.: A steady-state evaluation of the effects of propanthellne bromide and cholestyramine on the bioavailability of digoxin when administered as tablets or capsules. J. Clin. Pharmacol. 25(5), 360-364 (1985).
17. Jahnchen E, Meinertz T, Gilfrich HJ et al.: Enhanced elimination of warfarin during treatment with cholestyramine. Br. J. Clin. Pharmacol. 5(5), 437-440 (1978).
18. Malloy MJ, Ravis WR, Pennell AT et al.: Effect of cholestyramine resin on single dose valproate pharmatokinetics. Int. J. Clin. Pharmacol. Ther 34(5), 208-211 (1996).
19. Schrott HG, Stein EA, Dujovne CA et al.: Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am. J. Cardiol. 75(1), 34-39 (1995).
20. Hibbard DM, Peters JR, Hunninghake DB: Effects of cholestyramine and colestipol on the plasma concentrations of propranolol. Br. J. Clin. Pharmacol. 18(3), 337-342 (1984).
21. Donovan JM, Stypinski D, Stiles MR et al.: Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc. Drugs Ther. 14(6), 681-690 (2000).
22. Donovan JM, Kisicki JC, Stiles MR et al.: Effect of colesevelam on lovastatin pharmacokinetics. Ann. Pharmacother. 36(3), 392-397 (2002).
23. Jones MR, Baker BA, Mathew P: Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics. Clin. Pharmacokinet. 43(13), 943-950 (2004).
24. Knopp RH, Tsunehara C, Retzlaff BM et al.: Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study. Metabolism 55(12), 1697-1703 (2006).
25. Knopp RH, Dujovne CA, Le Beaut A et al.: Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled Phase III clinical studies. Int. J. Clin. Pract. 57(5), 363-368 (2003).
26. Davidson MH, Dillon MA, Gordon B et al.: Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch. Intern. Med. 159(16), 1893-1900 (1999).
27. Insull W Jr, Toth P, Mullican W et al.: Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin. Proc. 76(10), 971-982 (2001).
28. Knapp HH, Schrott H, Ma P et al.: Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am. J. Med. 110(5), 352-360 (2001).
29. Hunninghake D, Insull W Jr, Toth P et al.: Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL-cholesterol additiveiy. Atherosclerosis 158(2), 407-416 (2001).
30. Davidson MH, Toth P, Weiss S et al.: Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin. Cardiol. 24(6), 467-474 (2001).
31. Bays HE, Davidson M, Jones MR et al.: Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am. J. Cardiol. 97(8), 1198-1205 (2006).
32. Zema MJ: Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. Am. J. Ther. 12(4), 306-310 (2005).
33. Kosoglou T, Statkevich P, Reyderman L et al.: Effects of selected drugs on exposure to ezetimibe (abstract). Eur Heart J. 24, 462 (2003).
34. Bays H, Rhyne J, Abby S et al.: Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr. Med. Res. Opin. 22(11), 2191-2200 (2006).
35. Xydakis AM, Guyton JR, Chiou P et al.: Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. Am. J. Cardiol. 94(6), 795-797 (2004).
36. McKenney J, Jones M, Abby S: Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. Curr. Med. Res. Opin. 21(9), 1403-1412 (2005).
37. Devaraj S, Autret B, Jialal I: Effects of colesevelam hydrochloride (WelChol) on biomarkers of inflammation in patients with mild hypercholesterolemia. Am. J. Cardiol. 98(5), 641-643 (2006).
38. Cromwell WC, Otvos JD: Low-density lipoprotein particle number and risk for cardiovascular disease. Curr. Atheroscler. Rep. 6(5), 381-387 (2004).
39. Blake GJ, Otvos JD, Rifai N et al.: Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 106(15), 1930-1937 (2002).
40. Kuller L, Arnold A, Tracy R et al.: Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler. Thromb. Vasc. Biol. 22(7), 1175-1180 (2002).
41. Rosenson RS. Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. Atherosclerosts 185(2), 327-330 (2006).
42. Rosenson RS, Otvos JD, Freedman DS: Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am. J. Cardiol. 90(2), 89-94 (2002).
43. Bays HE, Goldberg RB: The 'forgotten' bile acid sequestrants: is now a good time to remember? Am. J. Ther. 14(6). 567-580 (2007).
44. Zieve FJ, Kalin MF, Schwartz SL et al.: Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with Type 2 diabetes. Clin. Ther. 29(1), 74-83 (2007).
45. Cariou B, Duran-Sandoval D, Kuipers F et al.: Famesoid X receptor: a new player in glucose metabolism? Endocrinology 146(3), 981-983 (2005).
46. Claudel T, Staels B, Kuipers F: The Famesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler. Thromb. Vasc. Biol. 25(10), 2020-30 (2005).
47. Zollner G, Fickert P, Fuchsbichler A et al.: Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J. Hepatol. 39(4), 480-488 (2003).
48. Tamehiro N, Shigemoto-Mogami Y, Kakeya T et al.: Sterol regulatory element-binding protein-2- and liver X receptor-driven dual promoter regulation of hepatic ABC transporter A1 gene expression: mechanism underlying the unique response to cellular cholesterol status. J. Biol. Chem. 282(29), 21090-21099 (2007).
49. Rivers SM, Kane MP, Busch RS et al.: Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. Endocr. Pract. 13(1), 11-16 (2007).
50. Hanus M, Zhorov E. Bile acid salt binding with colesevelam HCl is not affected by suspension in common beverages. J. Pharm. Sci. 95(12), 2751-9 (2006).
51. Denke MA: Cholesterol-lowering diets. A review of the evidence. Arch. Intern. Med. 155(1), 17-26 (1995).
52. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285(19), 2486-2497 (2001).
53. Graham I, Atar D, Borch-Johnsen K et al.: European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur. J. Cardiovasc. Prev. Rehabil. 14(Suppl. 2), S1-S113 (2007).
54. British Cardiac Society, British Hypertension Society, Diabetes UK et al.: JBS 2: the Joint British Societies' guidelines for prevention of cardiovascular disease in clinical practice. Heart 91 (Suppl. V), v1-v52 (2005).
55. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 231(4), 360-381 (1975).
56. Wierzbicki AS: FIELDS of dreams, fields of tears: a perspective on the fibrate trials. Int. J. Clin. Pract. 60(4), 442-449 (2006).
57. Rubins HB, Robins SJ, Collins D et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341(6), 410-418 (1999).
58. Keech A, Simes RJ, Barter P et al.: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366(9500), 1849-1861 (2005).
59. Downs JR, Clearfield M, Weis S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279(20), 1615-1622 (1998).
60. Brown BG, Zhao XQ, Chatt A et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 345(22), 1583-1592 (2001).
61. Brown G, Albers JJ, Fisher LD et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med. 323(19), 1289-1298 (1990).
62. Whitney EJ, Krasuski RA, Personius BE et al.: A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann. Intern. Med. 142(2), 95-104 (2005).
63. Kastelein JJ, Akdim F, Stroes ES et al.: ENHANCE investigators: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358(14), 1431-1443 (2008).
64. Avorn J, Monette J, Lacour A et al.: Persistence of use of lipid-lowering medications: a cross-national study. JAMA 279(18), 1458-1462 (1998).
65. Braunlin W, Zhorov E, Guo A et al.: Bile acid binding to sevelamer HC1. Kidney Int.. 62(2), 611-619 (2002).
66. Shantouf R, Budoff MJ, Ahmadi N et al.: Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients. Am. J. Nephrol. 28(2), 275-279 (2007).
67. Date T, Shigematsu T, Kawashita Y et al.: Colestimide can be used as a phosphate binder to treat uraemia in end-stage renal disease patients. Nephrol. Dial. Transplant. 18(Suppl. 3), iii90-iii93 (2003).
68. Suzuki T, Oba K, Futami-Suda S et al.: Effects of colestimide on blood glucose-lowering activity and body weight in patients with type 2 diabetes and hypercholesterolemia. J. Nippon Med. Sch. 74(1), 81-84 (2007).
69. Suzuki T, Oba K, Igari Y et al.: Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36). levels in patients with Type 2 diabetes mellitus complicated by hypercholesterolemia. J. Nippon Med. Sch. 74(5), 338-343 (2007).
70. Steinmetz KL, Schonder KS: Colesevelam: potential uses for the newest bile resin. Cardiovasc. Drug Rev. 23(1), 15-30 (2005).
71. Duivenvoorden R, Nederveen AJ, de Groot E et al.: Atherosclerosis imaging as a benchmark in the development of novel cardiovasular drugs. Curr. Opin. Lipidol. 18(6), 613-621 (2007).
72. Bots ML: Carotid intima-media thickness as a surrogate marker for cardiovascular disease in intervention studies. Curr. Med. Res. Opin. 22(11), 2181-2190 (2006).
73. Lorenz MW, Markus HS, Bots ML et al.: Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115(4), 459-467 (2007).
74. Zhao XQ, Phan BA, Chu B et al.: Testing the hypothesis of atherosclerotic plaque lipid depletion during lipid therapy by magnetic resonance imaging: study design of Carotid Plaque Composition Study. Am. Heart J. 154(2), 239-246 (2007).